ACHC vs AZN

ACHC's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining earnings, and high leverage. The absence of an Altman Z-Score and negative ROE (-40.96%) raise significant bankruptcy risk concerns. Despite a modest forward P/E of 14.03 and strong recent earnings surprises, the company's negative profit margin (-33.29%) and massive year-over-year EPS decline (-89.1%) undermine its fundamentals. The stock's 5-year price drop of 61.4% and lack of dividend support further signal investor skepticism. Analysts recommend 'buy' but with limited conviction, as the underlying financial health remains fragile.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.